IRLAB Therapeutics AB (publ) (IRLAB_A) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to yet an inspiring quarterly presentation by research company iLab. Presenting today will be newly appointed CEO Kristina Torfgaard, Executive Vice President R&D Niklas Waters and CFO Viktor Sivic. After the presentation, there will be a Q&A with participating equity analysts. Hello and welcome, Kristina. Hello, good morning. Thank you. Good morning. You came on board Aerolab 1st of August. Could you please tell us a bit how this first few months have been with the company? Yes, so this is the first quarter for me as the CEO of Aerolab and it has been eventful and I have got quite a lot of very good insight in the company and it's a great company. And I would say that everything goes back to really the organization. It's a very experienced and dedicated team behind the company. And I'm very, very honored and it's great to take the lead and leading the company now where we have such a very important mission to develop new innovative treatments for people suffering from Parkinson's. And I'm very, very happy to be part of this team also and to be part of this journey that we are doing, because what we are really aiming to is to make sure that people with Parkinson's can get a much better life in the future. Yes, thank you, Kristina. We are all very thankful for what you are doing. So please go ahead with your Q3 presentation and I will be back for the Q&A. Thank you. So first slide. Next slide. This is our disclaimer. So today's agenda, I will introduce with giving you an update on the news for the Q3 period. I will then hand over to Niklas Water, Executive Vice President, Head of R&D. He will talk about the R&D update during the quarter. And then to hand over further to Victor Sievert, to CFO of the company, and he will talk about the financials. And at the en...